Meningioma is considered the most common primary benign brain tumor. It originates from the arachnoid cells of the leptomeninges surrounding the brain. The mainstay treatment of meningiomas is microsurgical resection. Meningioma prognosis depends on tumor grade, location, and patient age. Recently, using noncoding RNA as a prognostic and diagnostic biomarker for many tumors became a trend. Herein, we demonstrate the importance of non-coding RNAs, including microRNAs and lncRNAs in meningioma and their potential role in meningioma's early diagnosis, prognosis, histological grade, and radiosensitivity. In this review, many microRNAs were found to be upregulated in radioresistant meningioma cells such as . Moreover, there are many microRNAs downregulated in radioresistant meningioma cells such as microRNA-1275, microRNA-30c-1-3p, . Also, we highlight the possible use of non-coding RNAs as serum non-invasive biomarkers and their potential role as therapeutic targets to treat high-grade meningiomas. Recent studies show that are downregulated in the serum of patients with meningiomas. Additionally, microRNA-106a-5p, microRNA-219-5p, microRNA-375, and microRNA-409-3p are found to be upregulated in the serum of patients with meningioma. We also found that there are many deregulated microRNAs in meningioma cells that can be used as potential biomarkers for meningioma diagnosis,

Background: Parasagittal and Parafalcine Meningiomas (PSPF) have a higher rate of recurrence, increased risk of postoperative morbidities, and less favorable outcomes after stereotactic radiosurgery compared to other ocations. Herein, we try to find factors associated with treatment failure after radiosurgery in patients with PSPF meningiomas. Methods: We retrospectively reviewed records of 104 patients with 130 Gamma Knife® Radiosurgery (GKRS) treatments for individual meningiomas at a single institution. 38 were PSPF compared to 92 in non-PSPF locations. Results: The PSPF group showed a significantly higher rate of surgical intervention after radiosurgery compared to the non-PSPF group (18.4% vs 4.4, p = 0.008 in univariate analysis). The relative risk for a PSPF tumor requiring surgery after GKRS was 4.24, with an odds ratio of 4.97 (95% CI: [1.32-13.63], p = 0.015). The average tumor size between the PSPF group and the non-PSPF group was 3.53 cm3 and 2.28 cm3, respectively; this difference was statistically significant (p = 0.035) on univariant analysis, but not multivariate (p = 0.125). In the whole sample, for tumors >5 cm3, the relative risk ratio for needing surgery after GKRS was 6.23 with an odds ratio of 8.32 (95% CI: [2.25-30.67], p = 0.0015). Both PSPF and non-PSPF meningiomas were similar in gender, follow-up length, prior surgical intervention, and WHO grades. Conclusion: Meningiomas’ outcome and response to radiosurgery depend on their location. We have two possible explanations. First, PSPF tumors are located near sensitive cerebral cortex areas. Second, the tumor’s mutational profile affects meningiomas’ location and prognosis.

Trigeminal neuralgia (TN) presents with symptoms of intense recurrent shock-like brief pain localized to specific areas of the face innervated by the fifth cranial nerve. The pathology of trigeminal neuralgia is attributed to the fifth cranial nerve compression or demyelination. Most cases of this diagnosis are not due to bony structures, making this case an uncommon presentation of trigeminal neuralgia. Herein, we present a case of trigeminal neuralgia due to an intraosseous meningioma that formed along the left petrous bone, resulting in trigeminal nerve compression. On head computed tomography (CT), osteomatous growths along the left petrous bone were noticed compressing the trigeminal nerve. After trigeminal nerve decompression and drilling out the protruding part of the petrous bone through middle cranial fossa craniotomy, the patient's symptoms were completely improved postoperatively and at the two-month follow-up. To our knowledge, there are only four reported cases of trigeminal neuralgia caused by petrous bone compression in the literature. We emphasize the significance of considering petrous bone lesions as a cause of trigeminal neuralgia.

Neurological tumors, such as gliomas and meningiomas are rarely presented by movement disorders. Early detection of neurological tumors, both basal ganglia arising tumors and basal ganglia-sparing ones, presenting with movement disorders is crucial to prevent any further deficits.

Schwannomas are benign tumors composed of neoplastic Schwann cells and rarely occur in the central nervous system. Schwannomas account for approximately 8% of intracranial tumors and most commonly originate from cranial nerve VIII at the cerebellopontine angle in the posterior fossa. Herein, we report two cases of vestibular schwannomas extending in the middle fossa. The first case shows a 51-year-old male who presented with a history of mild headaches for one year associated with acute nausea, vomiting, and wordfinding difficulties. Imaging revealed a large multicystic contrast-enhancing lesion in the left middle cranial fossa. The middle fossa lesion was resected with pathology indicating a schwannoma. The second case shows a 63-year-old woman who presented with seizures, right-sided hearing loss, and right-sided facial weakness. On MRI, she is found to have a large right middle fossa lesion originating from the right internal auditory canal and consistent with vestibular schwannoma with a 9 mm leftward midline shift. The histopathologic examination of the excised tumor indicated a schwannoma. Schwannomas most commonly occur in the posterior fossa when they present intracranially. However, in rare occurrences, they may present as middle fossa masses with significant intracranial compression.